Sulindac (Clinoril® -MSD)

Huskisson EC. Anti-inflammatory drugs. Semin Arthritis Rheum 1977; 7: 1–20.

Package Insert, Merck, Sharp and Dohme.

Shen TY Witzel BC Jones H Linn BO Synthesis of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)-benzylidenyl]-indene-3-acetic acid. Fed Proc 1972; 31: 577.

Van Arman CG Risley EA Nuss GW Hucker HB Duggan DE. Pharmacology of sulindac. In: Huskisson EC Franchimont P eds. Clinoril in the treatment of rheumatic disorders. New York: Raven Press, 1976: 9–36.

Willkens RF. The use of nonsteroidal antiinflammatory agents. JAMA 1978; 240: 1632–5.

Duggan DE Hooke KF Noll RM Hucker HB Van Arman CG. Comparative disposition of sulindac and metabolites in five species. Biochem Pharmacol 1978; 27: 2311–20.

Duggan DE Hare LE Ditzler CA Lei BW Kwan KC. The disposition of sulindac. Clin Pharmacol Ther 1977; 21: 326–35.

Delcambre B. The sulindac profile: use of sulindac in hospital and private practice, multicenter study in general practice. Eur J Rheum Inflamm 1978; 1: 47–50.

Huskisson EC. Sulindac. Eur J Rheum Inflamm 1978; 1: 3–5.

Brogden RN Heel RC Speight TM Avery GS. Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs 1978; 16: 97–114.

Hucker HB Stauffer SC White SD Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-[p(methylsulfinyl)-benzylidenyl] indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos 1973; 1: 721–36.

Personal communication, P. Olivero, Merck, Sharp and Dohme, Merck and Co., Inc. (June 5) 1979.

Duggan DE Hooke KF Risley EA Shen TY Van Arman CG. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 1977; 201: 8–13.

Kwan KC Duggan DE Van Arman CG Shen TY. Sulindac: chemistry, pharmacology and pharmacokinetics. Eur J Rheum Inflamm 1978; 1: 9–11.

Gengos D. Long term experience with sulindac in the treatment of osteoarthritis. Eur J Rheum Inflamm 1978; 1: 51–4.

Huskisson EC. Experience with sulindac in rheumatoid and osteoarthritis. Eur J Rheum Inflamm 1978; 1: 12–15.

Bordier PH Kuntz D. Sulindac: clinical results of treatment of osteoarthritis. Eur J Rheum Inflamm 1978; 1: 27–30.

Calabro JJ Sumner Y Andelman SY A Multicenter trial of sulindac in osteoarthritis of the hip. Clin Pharmacol Ther 1977; 22: 358–63.

Chahade WH Josef H. Clinical evaluation of the efficacy and tolerance of sulindac in patients with osteoarthritis of the hip and/or knee during 144 weeks: comparative study with aspirin during the first 96 weeks. Eur J Rheum Inflamm 1978; 1: 41–4.

Andrade L Fernandez A. Sulindac in the treatment of osteoarthritis: a double-blind 8-week study comparing sulindac with ibuprofen and 96 weeks of long-term therapy. Eur J Rheum Inflamm 1978; 1: 36–40.

Reynolds PMG Rhymer AR MacLeod MN Watson Buchannon W. Comparison of sulindac and aspirin in rheumatoid arthritis. Curr Med Res Opin 1977; 4: 485–91.

Caruso I Fumagalli M Tirrito M Double-blind study with a new anti-rheumatic drug, sulindac, in the treatment of rheumatoid arthritis; Comparison with acetylsalicylic acid. Eur J Rheum Inflamm 1978; 1: 58–65.

Calabro JJ. Sulindac in the treatment of gout: multicenter studies. Eur J Rheum Inflamm 1978; 1: 21–3.

Bröll H Eberl R Partsch G Preliminary results with the new non-steroidal anti-inflammatory agent sulindac compared to phenylbutazone in the treatment of ankylosing spondylitis. In: Huskisson EC Franchimont P eds. Clinoril in the treatment of rheumatic disorders. New York: Raven Press, 1976: 123–31.

Gadomski M Singer-Bakker H Braun HD. Sulindac: a double-blind clinical study of a new anti-inflammatory agent in the treatment of ankylosing spondylitis compared with phenylbutazone. In: Huskisson EC Franchimont P eds. Clinoril in the treatment of rheumatic disorders. New York: Raven Press, 1976: 133–9.

Zorzin L Carratelli L. Further studies with sulindac in sub-deltoid bursitis. Eur J Rheum Inflamm 1978; 1: 24–6.

Villiaumey J DiMenza C. Sulindac compared with oxyphenbutazone in the treatment of acute painful shoulder. In: Huskisson EC Franchimont P eds. Clinoril in the treatment of rheumatic disorders. New York: Raven Press, 1976: 161–5.

Rooney P Buchanan W Haigh BS Roylance PJ Rhymer AR. A clinical assessment in general practice of sulindac. Eur J Rheum Inflamm 1978; 1: 66–8.

Huskisson EC Scott J. Sulindac: trials of a new antiinflammatory drug. Ann Rheum Dis 1978; 37: 89–92.

Green D Given KM Ts'ao C Whipple JP Rossi EC. The effect of a new non-steroidal anti-inflammatory agent, sulindac, on platelet function. Thromb Res 1977; 10: 283–9.

Minsker DH Jordon P Kling P Welch T. The effect of sulindac and sulindac metabolites on arachidonate-induced lethality in rabbits; effect on human, guinea pig, dog and rat platelet activity. Thromb Res 1977; 11: 217–26.

Cohen A. Intestinal blood loss after a new antiinflammatory drug, sulindac. Clin Pharmacol Ther 1976; 20: 238–40.

Bianchi Porro G Petrillo M Fumagalli M Carratelli L. Endoscopic evaluation of the effects of a new anti-inflammatory drug, sulindac, on the gastric mucosa. Eur J Rheum Inflamm 1978; 1: 34–5.

Anderson RJ. Severe reaction associated with sulindac administration. N Engl J Med 1979; 300: 735–6.

Ryan JR Jain AK McMohan FG Vargas R. On the question of an interaction between sulindac and tolbutamide in the control of diabetes. Clin Pharmacol Ther 1977; 21: 231–3.